(NASDAQ: MGNX) Macrogenics's forecast annual revenue growth rate of -10.06% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 56.38%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.68%.
Macrogenics's revenue in 2025 is $154,050,000.On average, 4 Wall Street analysts forecast MGNX's revenue for 2025 to be $5,812,006,735, with the lowest MGNX revenue forecast at $2,523,612,920, and the highest MGNX revenue forecast at $9,450,930,385. On average, 3 Wall Street analysts forecast MGNX's revenue for 2026 to be $8,787,409,458, with the lowest MGNX revenue forecast at $4,510,958,095, and the highest MGNX revenue forecast at $14,431,911,386.
In 2027, MGNX is forecast to generate $5,589,171,715 in revenue, with the lowest revenue forecast at $4,970,255,646 and the highest revenue forecast at $6,208,087,783.